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Background
Most patients with hereditary hemochromatosis in the Caucasian population are homozygous
for the p.C282Y mutation in the HFE gene. The penetrance and expression of hereditary
hemochromatosis differ largely among cases of homozygous p.C282Y. Genetic factors might
be involved in addition to environmental factors. 
Design and Methods
In the present study, we analyzed 50 candidate genes involved in iron metabolism and evaluat-
ed the association between 214 single nucleotide polymorphisms in these genes and three phe-
notypic outcomes of iron overload (serum ferritin, iron removed and transferrin saturation) in a
large group of 296 p.C282Y homozygous Italians. Polymorphisms were tested for genetic asso-
ciation with each single outcome using linear regression models adjusted for age, sex and alco-
hol consumption. 
Results
We found a series of 17 genetic variants located in different genes with possible additive effects
on the studied outcomes. In order to evaluate whether the selected polymorphisms could pro-
vide a predictive signature for adverse phenotype, we re-evaluated data by dividing patients in
two extreme phenotype classes based on the three phenotypic outcomes. We found that only
a small improvement in prediction could be achieved by adding genetic information to clinical
data. Among the selected polymorphisms, a significant association was observed between
rs3806562, located in the 5’UTR of CYBRD1, and transferrin saturation. This variant belongs to
the same haplotype block that contains the CYBRD1 polymorphism rs884409, found to be
associated with serum ferritin in another population of p.C282Y homozygotes, and able to
modulate promoter activity. A luciferase assay indicated that rs3806562 does not have a signif-
icant functional role, suggesting that it is a genetic marker linked to the putative genetic modi-
fier rs884409. 
Conclusions
While our results support the hypothesis that polymorphisms in genes regulating iron metabo-
lism may modulate penetrance of HFE-hereditary hemochromatosis, with emphasis on
CYBRD1, they strengthen the notion that none of these polymorphisms alone is a major mod-
ifier of the phenotype of hereditary hemochromatosis.
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Introduction 
Hereditary hemochromatosis is a heterogeneous disor-
der at both genetic and phenotypic levels. HFE-hereditary
hemochromatosis is the most common form in Caucasian
populations and homozygosity for p.C282Y mutation is
the genotype most frequently associated with iron over-
load and related complications.1 HFE-hereditary
hemochromatosis may lead to accumulation of iron in tis-
sues and iron-related complications, but penetrance and
expression vary greatly among p.C282Y homozygotes.
Environmental and genetic factors have been implicated:
blood loss, alcohol intake, coexistence of chronic hepatitis
B and C, and non-alcoholic fatty liver disease can influence
clinical manifestations in humans.1,2 Animal studies
showed that the genetic background modulates the
expression of the disease3 and identified several candidate
modifier regions in HFE-knock-out mice.4 In humans, a
high concordance of iron indices and/or iron-related dis-
ease has been found among related patients with HFE-
hereditary hemochromatosis, supporting the existence of
genetic modifiers influencing phenotype expression.5,6
Association studies between genetic markers and disease
phenotype have given conflicting results.7-14 More recently,
candidate gene studies revealed significant associations
between single nucleotide polymorphisms (SNPs) in genes
involved in iron metabolism and indices of iron overload
in p.C282Y homozygotes. Milet et al. focused on two bio-
logically relevant gene categories: genes involved in non-
HFE-hereditary hemochromatosis (TFR2, HAMP, and
SLC40A1) and genes involved in the regulation of hepcidin
expression (BMP2, BMP4, HJV, SMAD1, 4 and 5, and IL6).
They found an association between the SNP rs235756 of
the bone morphogenetic protein-2 (BMP2) gene and
serum ferritin in a large series of French patients.15
Constantine et al. found that the SNP rs884409 in CYBRD1
was a possible novel modifier specific to HFE-hereditary
hemochromatosis, but were unable to confirm the associ-
ation with the BMP2 rs23575616. Moreover, genome-wide
association studies performed in the general population in
recent years have shown associations between SNPs of
transmembrane protease, serine 6 (TMPRSS6) and serum
iron17,18 and transferrin saturation,19 suggesting a relevant
involvement of TMPRSS6 in the control of iron homeosta-
sis. In the present study, we evaluated the association
between several SNPs in genes involved in iron metabo-
lism and three phenotypic outcomes of iron overload
(serum ferritin, iron removed and transferrin saturation) in
a group of p.C282Y homozygous Italians under the
assumption that these SNPs may act as modifiers of their
iron phenotype. 
Design and Methods
Subjects
We enrolled a group of 306 unrelated patients with HFE in the
study. All these patients were p.C282Y homozygotes attending
four centers in northern Italy (Milan, Verona, Genoa and Monza).
There was no selection based on disease severity. From the whole
database of each center, patients were selected based on the fol-
lowing inclusion and exclusion criteria. Inclusion criteria were:
p.C282Y homozygosity, availability of data on serum ferritin and
transferrin saturation before iron depletion, good quality DNA,
and information about age, sex and alcohol intake. Patients with a
previous history of regular blood donations were excluded from
the study. Data on total iron removed were available for 211
patients. A group of 114 healthy controls were recruited among
blood donors from the same geographic area of the patients only
to further validate the quality of the genotype data (calculation of
the Hardy-Weinberg equilibrium to check for bias and mistakes in
genotyping). Patients and controls gave their informed consent to
participation in this study. The Lombardy Region and University
of Milano-Bicocca research fellowship committees approved the
study.
Iron indices
Serum ferritin levels, total iron removed and percentage of
transferrin saturation were used as markers of the expression of
hereditary hemochromatosis among patients. Serum ferritin and
transferrin saturation were measured at the time of diagnosis
before phlebotomy therapy; total iron removed was calculated
based on the number of phlebotomies performed to achieve iron
depletion, as previously reported.20
Extraction of DNA from blood
Blood samples for DNA extraction were collected from all sub-
jects into tubes containing EDTA. Genomic DNA was extracted
from the whole blood of each subject using the Wizard® Genomic
DNA Purification kit (Promega, Madison, WI, USA), and stored at
-20°C before use. DNA samples were adjusted to a concentration
of 50 ng/mL.
Selection of single nucleotide polymorphisms 
Two hundred and fourteen TagSNPs within 50 candidate genes
were analyzed. Two hundred and eleven were selected by
Haploview Tagger21 for the CEU population to be screened with a
custom-designed 384-plex VeraCode GoldenGate genotyping
assay on an Illumina BeadXpress Reader platform (Illumina Inc.
San Diego, CA, USA). Three (rs855791 in TMPRSS6, rs884409 and
rs3806566 in CYBRD1) were selected a posteriori based on previous
results showing significant correlations with iron status in the gen-
eral population18 and in patients with HFE-hereditary hemochro-
matosis,16 respectively, and analyzed by direct sequencing. More
information on the SNP selection criteria is reported in the Online
Supplementary Design and Methods section, and the whole list of
SNPs analyzed is given in the Online Supplementary Table S1. 
Genotyping of single nucleotide polymorphisms 
SNP genotyping was performed using the GoldenGate
Genotyping assay on an Illumina BeadXpress Reader platform
according to the manufacturer’s protocol. GenomeStudio software
was used to call genotypes (see Online Supplementary Design and
Methods section). Illumina results were further validated by
sequencing 100 samples for 12 SNPs on an ABI Prism 3130 Avant
Automatic Sequencer (Applied Biosystems, Foster City, CA, USA).
Dual-luciferase reporter assay 
DNA fragments (415 bp) of the CYBRD1 gene were obtained
from genomic DNA of two individuals, each one carrying the TT
and CC genotype of the SNP rs3806562, by polymerase chain
reaction (forward primer: 5’-
ggCTCgAgggCTggACCAgATCAAAgAA-3’; reverse primer: 5’-
gggATATCgCCTgCCCTCTTTCCAACATT-3’). The polymerase
chain reaction products, which did not include either rs3806566 or
rs884409, were cloned into the pGL4.13 plasmid vector (Promega
Corp., Madison, WI, USA) upstream of the firefly luciferase gene,
by digestion with XhoI and EcoRV. Plasmid constructs were veri-
fied by direct sequencing. Plasmid DNA was isolated by Pure
YieldTM Plasmid Miniprep System kit (Promega Corp., Madison,
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WI, USA) for transfection. The recombinant plasmids were co-
transfected with pGL4.74 plasmid (carrying the hRluc/Tk reporter
gene as an expression control) into hepatoma carcinoma cells
(Huh-7) by Lipofectamine 2000 (Life-Technologies Corp.,
Carlsbad, CA, USA). The pGL4.13 basic plasmid was also co-
transfected with pGL4.74 as a negative control. After incubation
for 48 h, cells were lysed and firefly and renilla luciferase activities
were measured by a Glomax Multi JR luminometer according to
manufacturer’s protocols (Promega Corp., Madison, WI, USA).
Each construct was tested in triplicate, and the transfection exper-
iments were performed three times independently. Data are
expressed as mean ± standard deviation. Luciferase activities were
compared by the Mann-Whitney test, using Prism 3.2 software
(GraphPad Software, San Diego, CA, USA).
Statistical methods
Stringent quality control criteria were applied to all samples and
genotype data. A per-SNP genotype rate threshold of 95% was
used. Identity-by-state values were calculated for pairs of subjects
to identify duplicates or possibly related subjects. For any pair
with more than 95% identical SNP genotypes, the sample with
the lower call rate was removed from the analysis. SNPs with a
minor allele frequency less than 0.6% were also removed. To
check for genotyping errors, the Hardy-Weinberg equilibrium for
each SNP was tested among the controls with  Pearson’s χ2 test
statistic. SNPs that deviated from the Hardy-Weinberg equilibrium
were excluded from the analysis. Iron indices were analyzed as
continuously distributed outcomes and normalized using a log
transformation. A linear regression model was fitted to evaluate
the effect on the three outcomes of  age, sex and alcohol consump-
tion (g/day). Each SNP was tested for association with each single
outcome by using separate linear regression models adjusted for
age, sex and alcohol consumption. Genotypic association was
considered and an additive genetic model was assumed. SNPs
were ranked according to their uncorrected P-value and top
ranked SNPs for each outcome were defined as those with P<0.05.
The false discovery rate, as computed by the q value, was applied
to adjust for multiple comparisons, using a threshold rate of <0.2.
Interactions between pairs of top ranked SNPs with each outcome
were evaluated by adding product terms to a multiple regression
linear model, adjusted for age, sex and alcohol consumption.
Multiple comparison adjustment was ignored while assessing the
significance of the interaction term. In order to evaluate whether
SNPs could provide a predictive signature for adverse phenotype,
we re-evaluated data by dividing patients with HFE-hereditary
hemochromatosis into two extreme iron-related phenotype class-
es. Identification of an extreme adverse phenotype, based on fer-
ritin, iron removed and transferrin saturation values, was per-
formed using principal component analysis, based on a correlation
matrix, fitted on 209 patients with non-missing values for all three
hematologic parameters. The component retaining the highest
proportion of variance (principal component analysis first compo-
nent) was used as a pseudo-marker and cut into tertiles, using the
first and third ones to define an extreme binary phenotype. Top
ranked SNPs were included in classification procedures using four
different algorithms; support vector machine (SVM22), random for-
est (RF22), ridge penalized logistic regression (PEN22) and K-nearest
neighbors (KNN22). The classification performances of all algo-
rithms were evaluated using the area under the receiver operating
characteristic curve (AUC). The AUC for each procedure was
computed using class probability i.e. the estimated probability of
being a “case” (i.e. of being in the highest tertile of the combined
hematologic parameters estimated via leave-one-out cross valida-
tion (LOOCV22). Class probability was estimated on the out of the
bag sample to reduce the bias of evaluating a classification model
on the same data used to build it. In order to estimate the best
number of SNPs to use, the cross-validation procedure was repeat-
ed for varying number of SNPs. For every run of the LOOCV algo-
rithm, all SNPs are ranked according to the size of the odds ratio
estimated by a logistic model accounting for the SNP itself, age,
sex and alcohol consumption. A classification model was then
built for increasing number of SNPs, from a model with only one
SNP (the most associated) to a model with all SNPs. The optimal
number of SNPs was then selected as the one with the highest
AUC. All methods require some fine tuning of parameters (e.g. the
k value in KNN). This was performed with cross-validation using
the whole set of SNPs. Tests for the equality of the AUC were per-
formed based on the method described by Delong et al.23 while
model prediction improvement was evaluated as suggested by
Pencina et al.24 More details are given in the Online Supplementary
Design and Methods. The analyses were performed using R and the
library GenABEL (genome-wide SNP association analysis R pack-
age version 1.7)25. 
Results
After imposing the quality control measures, 22 subjects
(10 HFE patients and 12 healthy controls) and 10 SNPs
were excluded from the analysis because of low call rate
and high frequency of SNPs that were identical-by-state.
In addition, sequence analysis of the SNPs rs3806566 and
rs884409 in the 5’UTR of CYBRD1, which were recently
found to be significantly associated with serum ferritin in
patients with HFE-hereditary hemochromatosis,16 con-
firmed that they are in complete linkage with rs3806562,
the SNPs we previously selected and validated.  For this
reason, only the latter SNP was retained for statistical
analysis. A total of 296 p.C282Y homozygous patients
(220 men, 76 women) and 102 healthy controls (86 men,
16 women) for 202 SNPs were finally considered. None of
these SNPs deviated from the Hardy-Weinberg equilibri-
um. The patients’ demographic data, alcohol intake,
hemoglobin and iron indices are reported in Table 1. Age
and sex were significantly associated with serum ferritin,
total iron removed and transferrin saturation (P<0.001),
while alcohol daily intake was significantly associated
with serum ferritin and total iron removed (P<0.001). 
Seventeen SNPs were associated with the iron indices
among patients (top ranked SNPs, uncorrected P<0.05).
Their allele frequencies were compared to those in the
CEU population (Table 2) and resulted similar with the
exception of the HFE SNP. 
For each single outcome, the top ranked associated SNPs
with their location within the gene and the worst allele in
terms of more severe phenotype are reported in Table 3.
s. Pelucchi et al.
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Table 1. Median and (range) of age, alcohol intake, hemoglobin and serum iron
indices in p.C282Y homozygotes divided by sex.
Missing All patients Males Females
(%) (N=296) (N=220) (N=76)
Age (years) 0 45.5 (11-77) 43 (11-76) 56 (21-77)
Alcohol intake (g/day) 0 10 (0-250) 10 (0-250) 5 (0-60)
Hemoglobin (g/dL) 22.6 14.8 (9.0-18.7) 15.0 (9.0-18.7) 13 (9.4-16.9)
Transferrin saturation (%) 2.4 85 (30-100) 86 (41-100) 80 (30-100)
Serum ferritin (mg/L) 0 1060 (31-13136) 1209 (32-13136) 552.5 (31-5089)
Iron removed (g) 28.7 7 (0.5-41) 8 (1.6-41) 4.4 (0.5-25)
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Serum ferritin was associated with rs12467409, rs9325886
and rs17804636, belonging to candidate genes BMPR2,
BMP9 and SMAD8, respectively. Total iron removed was
associated with rs3178250, rs762642, rs12467409,
rs11204215, rs1800702, rs149411, rs11684885 and
rs3780474, belonging to candidate genes BMP2, BMP4,
BMPR2, BMP9, HFE, DMT1, HIF2A and IRP1, respective-
ly. Transferrin saturation was associated with rs4401458,
rs2292915, rs701753, rs773050, rs701754, rs17554 and
rs3806562, belonging to candidate genes BMPR1B, NEO1,
CP and CYBRD1, respectively. The effect of the top
ranked SNP is expressed in terms of fold-change induced
on the estimated value of the outcome by adding a single
worst allele and after adjusting for age, sex and alcohol
consumption. After correction for multiple comparisons, a
significant association, adjusted for age, sex and alcohol
consumption, was detected between a SNP located in
CYBRD1, rs3806562, and transferrin saturation (uncorrect-
ed P<0.001, false discovery rate=0.07). Observed mean
transferrin saturation levels were 0.93 among TT geno-
types, 0.90 among TC genotype and 0.85 among CC
genotypes. 
In vitro functional assays of rs3806562 did not show sig-
nificant differences between constructs carrying the C or
the T allele (CC: 1.26±0.28, TT: 2.11±1.48 Relative
Luciferase Unit, P=NS). 
We found two suggestive but not significant interactions
between pairs of the 17 top ranked SNPs, one associated
with total iron removed (rs149411 and rs762642, uncor-
rected P=0.027) and one associated with transferrin satu-
ration (rs773050 and rs4401458, uncorrected P=0.02).
Figure 1 shows interaction plots of the estimated levels of
these indices as a function of SNP genotypes. 
In order to evaluate whether SNPs could provide a pre-
dictive signature for adverse phenotype, we re-evaluated
data using principal component analysis as described in
the Design and Methods section. The principal component
analysis first component (hereafter called ‘pseudo-mark-
er’) accounted for 62.4% of the total variance of iron
indices and reflected the overall iron load (loadings: serum
ferritin=0.64, transferrin saturation=0.43, total iron
removed=0.64). High levels of the three indices, therefore,
resulted in high values of the pseudo-marker and vice versa.
Based on the first and third tertiles of the pseudo-marker
we categorized patients as controls (mild phenotype) or
cases (adverse phenotype). In this way, the sample was
Genetic modifiers of the HFE-HH phenotype
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Table 3. SNPs associated with variability of serum ferritin, iron removed and transferrin saturation. 
Outcome SNP Gene symbol Location Worst N. Fold change* P value°
allele (95% CI)
Serum ferritin rs12467409 (G/T) BMPR2 Intron T 293 1.26 (1.02-1.58) 0.036
rs9325886 (C/A) BMP9 3’UTR C 296 1.39 (1.04-1.86) 0.026
rs17804636 (A/G) SMAD8 3’UTR G 296 1.43 (1.06-1.92) 0.019
Iron removed rs3178250 (T/C) BMP2 3’UTR T 211 1.19 (1.02 -1.37) 0.023
rs762642 (T/G) BMP4 Intron G 210 1.16 (1.02 -1.33) 0.030
rs12467409 (G/T) BMPR2 Intron T 208 1.30 (1.03 -1.64) 0.026
rs11204215 (A/C) BMP9 5’UTR A 211 1.22 (1.02 -1.46) 0.028
rs1800702 (C/G) HFE 5’UTR C 211 1.56 (1.01-2.38) 0.043
rs149411 (C/T) DMT1 3’UTR T 211 1.18 (1.02 -1.35) 0.025
rs11684885 (G/T) HIF2A Intron A 211 1.16 (1.01 - 1.33) 0.041
rs3780474 (A/C) IRP1 Intron C 211 1.21 (1.06-1.38) 0.005
Transferrin saturation rs4401458 (T/C) BMPR1B Intron T 289 1.23 (1.02 - 1.49) 0.031
rs2292915 (C/T) NEO1 Intron C 287 1.21 (1.00-1.47) 0.046
rs701753 (A/T) CP Coding A 288 1.56 (1.06-2.30) 0.023
rs773050 (A/G) CP Intron G 289 1.45 (1.002-2.09) 0.048
rs701754 (A/T) CP Intron A 288 1.32 (1.04-1.67) 0.022
rs17554 (G/A) CYBRD1 Intron G 289 1.23 (1.02-1.48) 0.034
rs3806562 (T/C) CYBRD1 5’UTR T 288 1.54 (1.21-1.96) <0.001
*Adjusted for age, gender and alcohol intake in a multiple linear regression model; ° P value uncorrected for multiple testing.
Table 2. Allelic frequencies in p.C282Y homozygotes and the CEU pop-
ulation of the 17 SNPs associated with the outcomes (top ranked
SNPs, uncorrected P<0.05). 
SNP CEU allelic frequencies Allelic frequencies
in p.C282Y 
homozygotes 
rs17554 (G/A) G: 0.55; A: 0.45 G: 0.67; A: 0.33
rs149411 (C/T) C: 0.58; T: 0.42 C: 0.63; T: 0.37
rs701753 (A/T) A: 0.92 ; T: 0.08 A: 0.94 ; T: 0.06
rs701754 (A/T) A: 0.85 ; T: 0.15 A: 0.84 ; T: 0.16
rs762642 (T/G) T: 0.61; G: 0.39 T: 0.56; G: 0.44
rs1800702 (C/G)* C: 0.61; G:0.39 C: 0.01; G:0.99
rs2292915 (C/T) C: 0.66; T: 0.34 C: 0.65; T: 0.35
rs3178250 (T/C) T: 0.81; C: 0.19 T: 0.72; C: 0.28
rs3780474 (A/C) A: 0.64; C:0.36 A: 0.64; C:0.36
rs3806562 (T/C) T: 0.85; C: 0.15 T: 0.84; C: 0.16
rs4401458 (T/C) T: 0.52; C: 0.48 T: 0.46; C: 0.54
rs9325886 (C/A) C: 0.93; A: 0.07 C: 0.94; A: 0.06
rs11204215 (A/C) A: 0.87; C: 0.13 A: 0.83; C: 0.17
rs11684885 (G/T) G: 0.66; T: 0.34 G: 0.62; T: 0.38
rs12467409 (G/T) G: 0.86; T: 0.14 G: 0.87; T: 0.13
rs17804636 (A/G) A: 0.92; G: 0.08 A: 0.93; G: 0.07
rs773050 (A/G) A: 0.94; G: 0.06 A: 0.94; G: 0.06
*HFE SNP.
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reduced to 140 patients (70 controls and 70 cases). The
average values of serum ferritin in the two groups were
619 mg/L in controls and 3718 mg/L in cases, with 85.5%
of cases and no controls having values 2000 mg/L and
91.3% of controls and only 1.5% of cases having values
below 1000 mg/L. The average levels for total iron
removed were 3.73 g and 16.88 g in controls and cases,
respectively, while the average percentages for transferrin
saturation were 67.2% in controls and 89.8% in cases. In
order to evaluate whether the top ranked SNPs could pro-
vide a predictive signature for adverse phenotype, we per-
formed a classification procedure based on four different
algorithms. For the classification algorithms we had to
remove subjects with at least one missing value in any of
the 17 selected SNPs. Overall we excluded two patients
and, therefore, performed the classification procedure on
69 controls and 69 cases. All models performed reasonably
well with an AUC greater than 65%. The best model was
the random forest one with an AUC of 76.8% using 14
SNPs (KNN 67.6% with 6 SNPs; PEN 67.0% with 16
SNPs; SVM 71.9% with 15 SNP). A predictive model
based on logistic regression including only age, sex and
alcohol consumption was also fitted. The resulting AUC
(70.0%) was lower than the best model with genetic
effect, but the difference was not statistically significant (P
value of the test for equality of AUC = 0.12). We then
evaluated the change in predicted probability using the
additional information from SNPs and we found that it
increased the estimated probability of being an event
among cases (sensitivity) to 2.97%, while reducing it
among controls (specificity) to 3%. To combine the latter
two quantities we computed the integrated discrimination
improvement which was close to, but still did not reach,
statistical significance (integrated discrimination improve-
ment, P-value = 0.06). These results suggest that the 17
selected SNPs provide little additional predictive power
for phenotype classification to the known clinical features.
Discussion
Homozygosity for the HFE p.C282Y mutation is neces-
sary but not sufficient to manifest a disease phenotype in
HFE-related hereditary hemochromatosis. The present
study shows that SNPs in several genes involved in iron
metabolism may modulate the expression of the disease in
p.C282Y homozygous patients. We analyzed three differ-
ent outcomes: transferrin saturation, serum ferritin and
total iron removed. Transferrin saturation is not a quanti-
tative index of iron overload, but might represent a quali-
tative index of alteration of iron homeostasis character-
ized by increased intestinal iron absorption and iron
release from macrophages and storage cells.26 Accordingly,
very high transferrin saturation is usually found in the
most severe forms of hereditary hemochromatosis and in
patients with ineffective erythropoiesis, both character-
ized by absent or very low level of hepcidin production
and high iron absorption.27 Serum ferritin is generally con-
sidered a good index of iron stores in hereditary
hemochromatosis28 and in our series serum ferritin corre-
lated significantly with the amount of iron removed
(r=0.613, P<0.0001). However, serum ferritin can be influ-
enced by hepatocellular necrosis, inflammation and alco-
hol intake, which may increase its concentration dispro-
portionately to the amount of iron overload. Phlebotomy,
with careful measurement of the amount of iron in the
blood removed, is the most accurate means of measuring
total body iron stores.29,30 However, it was not available for
all patients studied, this being a limitation when consider-
ing a large cohort of patients. 
Our sample is largely representative of the local popula-
tion of p.C282Y homozygotes since it covered a diverse
range of phenotypes, spanning from mild through moder-
ate to severe. It differed from the sample recruited in the
study by Milet et al. which, although from a region in
north-western Europe, was not fully representative of the
s. Pelucchi et al.
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Figure 1. Boxplots of the estimated total iron removed (IR) levels (log scale) according to rs149411 (DMT1) and rs762642 (BMP4) geno-
types (A) and of the estimated  transferrin saturation (TS) levels (logit scale) according to rs773050 (CP) and rs4401458 (BMPR1B) geno-
types (B). 
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population of p.C282Y homozygotes from which it was
drawn since it was, by the authors’ admission, rich in indi-
viduals with severe symptoms.31 In the present study we
found a significant association between a variant in
CYBRD1, rs3806562, and transferrin saturation. Moreover
we suggested a series of 17 SNPs which could have a pos-
sible additive effect on the studied outcomes. The SNP
rs3806562 of CBRYD1 is located in the 5’UTR of the gene
and is, therefore, likely to be functional. HapMap shows
that this SNP is in linkage disequilibrium with rs3806566
and rs884409 previously found to be associated with
serum ferritin in Australian p.C282Y homozygotes.16 We,
therefore, analyzed SNPs rs3806566 and rs884409 in our
cohort and confirmed that the three SNPs are in complete
linkage. However, luciferase assays did not show signifi-
cant differences in promoter activity between different
alleles of rs3806562. This suggests that SNP rs3806562 is a
genetic marker, located in the 5’UTR of CYBRD1, linked
to rs884409, a polymorphism able to modulate CYBRD1
promoter activity.16 High CYBRD1 activity might lead to
increased amounts of iron available for divalent metal
transporter 1 (DMT1) at the epithelial intestinal mucosa
and, in turn, to increased iron absorption and transferrin
saturation. In contrast to the Australian study, we were
not able to find correlations with quantitative indices of
iron overload (serum ferritin and total iron removed) and
we have no clear explanation for this discrepancy. Serum
ferritin and iron removed have their own intrinsic limits
(see above) and it is possible that acquired factors such as
dietary habits might contribute to modify the whole
amount of body iron. However, our results support the
hypothesis that CYBRD1 could be a modifier gene of iron
phenotype in patients with HFE-hereditary hemochro-
matosis. 
Our results also suggest that genes coding for the bone
morphogenetic proteins may be involved in the modula-
tion of iron overload in p.C282Y homozygotes. In partic-
ular, we found an association between three SNPs in
BMP9, SMAD8 and BMPR2 and serum ferritin. In addi-
tion, iron removed was associated with other polymor-
phisms present in BMP2, BMP4, BMP9, and BMPR2 (the
same SNP as associated with serum ferritin), and transfer-
rin saturation with another component of this pathway:
BMPR1B. Although we included rs235756 in BMP2 (previ-
ously reported as a genetic modifier in French patients
with HFE-hereditary hemochromatosis) in the analysis,
we could not confirm this result in our series, and the
rs3178250 in BMP2 that we found associated with iron
removed was not in linkage with rs235756. This could be
due to a difference in sample sizes between studies, but
also to the inherent heterogeneity related to disease, as
reported in other genetic studies of complex traits.32 All
these findings suggest that the expression of disease is not
only related to the impairment of HFE function but also
depends on the modulation exerted by the functional
bone morphogenetic protein on the expression of hepatic
hepcidin. BMP9 has been shown to be the most potent
inducer of hepcidin in vitro and also in mice.33 In vitro stud-
ies showed that SMAD8 and receptors type I and type II
(BMPR1A, BMPR1B, and BMPR2) are also hepcidin mod-
ulators,34 and that Bmpr1a is critically responsible for basal
hepcidin expression and is required (together with Acvr1)
for regulation of hepcidin in response to iron and bone
morphogenetic protein signaling in mice.35
Besides genes of the BMP/SMAD pathways and
CYBRD1, other genes involved in iron homeostasis
emerged from our study. Transferrin saturation was asso-
ciated with SNPs in genes involved in iron release from
storage cells (Cp). Previous studies showed the existence
of a complex interaction between Cp and Hfe in trans-
genic mice, suggesting that Cp is a modifier gene with a
protective effect on HFE-hereditary hemochromatosis.
Iron removed correlated with SNPs in DMT1, HIF2A,
IRP1, and HFE itself. Previous studies showed that DMT1
is over-expressed in HFE-hereditary hemochromatosis36
and that genetic loss of DMT1 modulates iron overload in
Hfe knockout mice.37 Although the great majority of our
patients carry identical HFE SNPs according to the obser-
vation that c.845G>A (p.C282Y) mutation is in complete
linkage disequilibrium with a unique haplotype,38 we
found that one HFE SNP (rs1800702) was associated with
variable iron removed. This finding is quite unexpected
because it indirectly suggests that the p.C282Y mutation
does not completely abolish HFE function. Although this
hypothesis needs to be validated, it is to be noted that
patients carrying null HFE mutations and Hfe knockout
mice have a more severe iron phenotype than their coun-
terparts carrying p.C282Y or a p.C282Y ortholog muta-
tion.3 Among the SNPs emerging from the analysis, some
(rs9325886, rs17804636, rs3178250, rs11204215,
rs1800702, rs149411, rs3806562) were in regulatory 5’ and
3’ UTR and one in the coding region (rs701753), suggest-
ing that all currently described genes in these pathways
might be candidates as modifier genes in p.C282Y
homozygotes and opening the way to functional studies
to confirm the effects of these variants on gene expression.
We were also able to suggest some interactive effects of a
couple of different SNPs on transferrin saturation and iron
removed. This result should be considered with caution
because the interaction analysis was not corrected for
multiple comparisons. However, the interactive effect on
iron removed of SNPs in BMP4 and DMT1, which are
involved in hepcidin regulation and intestinal iron absorp-
tion, respectively, is intriguing because it suggests that two
different pathways regulating iron status might cooperate
in modulating iron overload in p.C282Y homozygotes.
In order to evaluate whether the selected SNPs could
provide a predictive signature for adverse phenotype, we
re-evaluated our data by dividing our patients with HFE-
hereditary hemochromatosis into two extreme iron-relat-
ed phenotype classes. As extensively described in the
Design and Methods section here and in the Online
Supplement, we used principal component analysis to
extract relevant information from the set of data including
all three iron indices: serum ferritin, iron removed and
transferrin saturation. We compared the predictive per-
formance, as measured by a cross-validated AUC,
between various algorithms considering variable number
of SNPs with a model with only clinical characteristics and
found that only a small, but still not significant improve-
ment in prediction was achieved by adding genetic infor-
mation. This could be due either to an inappropriate defi-
nition of the phenotype or, more probably, to a strong
association between the binary phenotype and clinical
variables, namely alcohol consumption. 
We did not observe associations with SNPs of TF and
TMPRSS6, which emerged as modulators of some indices
of iron status in the general population in a recent
genome-wide association study.17 Transferrin heritability
ranged from 0.2 to 0.5 in different isolated populations in
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Italy39 and it seems reasonable to hypothesize that genetic
factors might influence transferrin saturation in hereditary
hemochromatosis by modulating transferrin levels, thus
increasing iron deposition and storage.19 A decreased
serum transferrin level is a common observation in hered-
itary hemochromatosis and it is generally considered sec-
ondary to hepatocellular iron overload,40 which our results
seem to confirm. We tested nine SNPs of TMPRSS6
including the common SNPs (rs4820268 and rs855791)
associated with serum iron and transferrin saturation in
the general population.17,18 Recent studies suggested that
rs855791 is a TMPRSS6 functional variant able to modu-
late hepcidin production,41 and that genetic loss of Tmprss6
in Hfe knock-out mice reduces systemic iron overload by
increasing Bmp/Smad signaling in an Hfe-independent
manner.42 Although these findings suggest that natural
genetic variation in the human ortholog TMPRSS6 might
modify the clinical penetrance of HFE-associated heredi-
tary hemochromatosis, our results indicate that the SNPs
studied did not have enough power to modify the iron
phenotype in our series. 
In conclusion, the present study suggests that SNPs in
genes regulating iron metabolism may modulate the pen-
etrance of HFE-hereditary hemochromatosis. These
results support the role of bone morphogenetic proteins as
possible modifiers of HFE-hereditary hemochromatosis
phenotype and further expand the observations on a larger
number of genes involved in iron absorption and release,
with emphasis on the 5’ UTR region in CYBRD1. Our
results also strengthen the notion that none of these poly-
morphisms alone is a major modifier of the hereditary
hemochromatosis phenotype, suggesting that the iron
phenotype in this disease is the result of a complex inter-
action between a major gene defect, genetic background
and environmental factors (alcohol intake in particular),
thus supporting the idea that HFE-hereditary hemochro-
matosis is a multifactorial disease. From a practical point
of view the identification of all these factors, including one
or more risk SNPs might add information on patients’ sus-
ceptibility to fully penetrant HFE-hereditary hemochro-
matosis and would help in adapting the clinical approach
better, defining follow-up and therapeutic strategies.
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